相关实验视频
Updated: Jul 27, 2025
05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
21.9K
在中高风险肺栓塞患者中,低剂量血栓消毒疗法与未分离的肝素对比
Ozgur Surgit1, Ahmet Güner1, İrem Türkmen1
1University of Health Sciences, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, İstanbul-Türkiye.
概括
在中高风险肺栓塞 (PE) 患者中,低剂量,长期的血栓抑制疗法 (TT) 显著降低了血液动力学失补偿和肺高血压,相比于未分离的肝素 (UFH). TT在急性PE管理方面表现出优异的结果.
科学领域:
- 心脏病学 心脏病学
- 肺部医学 肺部医学
- 血栓性疾病 血栓性疾病
背景情况:
- 中高风险肺栓塞 (PE) 患者与右心室功能障碍和心肌损伤可能受益于血栓治疗 (TT).
- 目前的治疗指南通常涉及未分离氨酸 (UFH),但其在预防这种特定PE亚组的不良结果方面的有效性需要进一步研究.
研究的目的:
- 为了比较中高风险PE患者中低剂量长期TT与UFH的临床结果.
- 评估TT在减少主要不良事件,包括死亡和血液动力学衰减等方面的有效性.
主要方法:
- 追溯评估83名被诊断患有急性PE的患者.
- 患者接受了低剂量,缓慢输注的TT或UFH治疗.
- 主要结局包括全因死亡,血液动力失补偿和严重出血;次要结局包括复发性PE,肺高血压和中度出血.
主要成果:
- 低剂量延长的TT在所有接受治疗的患者中都是成功的.
- 与UFH组相比,TT组显示低血压显著降低 (22%vs0%) 和血液动力失补偿 (0%vs11.9%).
- 超高血压组出现的次要终点 (19%比2.4%) 和肺高血压 (19%比0%) 的比率显著更高.
结论:
- 长时间的低剂量TT与中高风险PE患者的血液动力失补偿和肺高血压风险较低有关.
- 这种TT疗法提供了一个潜在的更安全,更有效的替代UFH管理急性中高风险PE.
相关概念视频
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
15
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
15
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
767
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
767
01:29Venous Thrombosis III: Interprofessional Care
11
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
11
01:27Pulmonary Embolism III: Nursing Management
17
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
17
01:29Pulmonary Embolism I: Introduction
10
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
10
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
223
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
223